Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

The three RAS genes—HRAS, NRAS and KRAS—are collectively mutated in one-third of
human cancers, where they act as prototypic oncogenes. Interestingly, there are rather …

One of the open questions in RAS biology is the existence of RAS dimers and their role in
RAF dimerization and activation. The idea of RAS dimers arose from the discovery that RAF …

Interdependence across time and length scales is common in biology, where atomic
interactions can impact larger-scale phenomenon. Such dependence is especially true for a …

RAS is a signaling protein associated with the cell membrane that is mutated in up to 30% of
human cancers. RAS signaling has been proposed to be regulated by dynamic …

RAS is the most frequently mutated oncogene in cancer and a critical driver of oncogenesis.
Therapeutic targeting of RAS has been a goal of cancer research for more than 30 years …

The protein K-Ras functions as a molecular switch in signaling pathways regulating cell
growth. In the human mitogen-activated protein kinase (MAPK) pathway, which is implicated …

KRAS homo‐dimerization has been implicated in the activation of RAF kinases, however,
the mechanism and structural basis remain elusive. We developed a system to study KRAS …

Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions
that interact with signalling effector proteins. Here, we report designed ankyrin repeat …

Ras dimerization is critical for Raf activation. Here we show that the Ras binding domain of
Raf (Raf-RBD) induces robust Ras dimerization at low surface densities on supported lipid …